Glenmark Pharmaceuticals announced that the company on 15 January 2021 redeeemed US $10,000,000 in aggregate principal amount of its 2021 Notes, representing approximately 5% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, no amount is outstanding in connection with the USD 200 million 4.5% Senior Notes due 2021 (2021 Notes). Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.